Boston Scientific announces the appointment of Caroline Bravo as the new vice president for the Rhythm Management business in Europe, Middle East and Africa (EMEA). Caroline will continue to build on and expand the company's leadership in technologies to treat cardiac rhythm disorders and heart failure and help protect against sudden cardiac arrest.

12 September 2023

Caroline brings over 30 years of experience to her new position, having held various leadership roles across sales, marketing, and business development. She is a driven and results-oriented leader with a passion for people development.

Caroline is a proven innovator who has a track record of success in developing and executing business growth. She is also a gifted people manager who can build strong relationships and get the best out of her team; she defines her leadership style as collaborative, believing in the power of diversity, and seeking to coach and empower top talents to use their diverse experiences and styles to achieve business objectives. Caroline is a highly respected leader in the healthcare industry, and her appointment is a testament to her skills and accomplishments.

Caroline is confident that she can make a significant contribution to the company's success in EMEA. She is also looking forward to working with the talented team in the region to improve the lives of patients. "I am thrilled to be appointed vice president of the Rhythm Management division in EMEA,” said Caroline. “I am inspired by Boston Scientific mission to advance innovation and growth in the region, and I am happy to be contributing to the company’s commitment to accelerate women in leadership growth. I look forward to working with our talented EMEA team to bring meaningful impact and value for the people we serve."

The company’s innovative solutions have helped transform the way physicians diagnose, treat cardiac rhythm disorders and heart failure and help protect against sudden cardiac arrest. With Caroline Bravo as vice president for Rhythm Management in EMEA, the company confirms its aim of bringing to market innovative medical solutions that improve the health of patients.